{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:24:59Z","timestamp":1790443499024,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.lpm.2016.11.014","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T18:54:10Z","timestamp":1483642450000},"page":"11-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cannabino\u00efdes de synth\u00e8se\u00a0: une nouvelle matrice des addictions"],"prefix":"10.1016","volume":"46","author":[{"given":"Amandine","family":"Scocard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Coscas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Karila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.lpm.2016.11.014_bib0005","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/13816128113199990622","article-title":"New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature","volume":"20","author":"Cottencin","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MAJ.0000000000000466","article-title":"Synthetic cannabinoids","volume":"350","author":"Mills","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.lpm.2016.11.014_bib0015","series-title":"European drug report\u00a02016: trends and developments","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.014_bib0020","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jemermed.2012.09.147","article-title":"Current \u201clegal highs\u201d","volume":"44","author":"Johnson","year":"2013","journal-title":"J Emerg Med"},{"issue":"5","key":"10.1016\/j.lpm.2016.11.014_bib0025","first-page":"661","article-title":"Emergency of synthetic drugs in the general landscape of addiction","volume":"62","author":"Karila","year":"2012","journal-title":"Rev Prat"},{"key":"10.1016\/j.lpm.2016.11.014_bib0030","series-title":"Perspectives on drugs \u2013 synthetic cannabinoids","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00216-012-6122-4","article-title":"Analysis of synthetic cannabinoids in \u201cspice-like\u201d herbal highs: snapshot of the German market in summer\u00a02011","volume":"404","author":"Simolka","year":"2012","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00213-013-3188-4","article-title":"Spicing things up: synthetic cannabinoids","volume":"228","author":"Spaderna","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1521-0391.2012.00240.x","article-title":"\u201cSpice\u201d and \u201cK2\u201d herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans","volume":"21","author":"Gunderson","year":"2012","journal-title":"Am J Addict"},{"issue":"1\u20133","key":"10.1016\/j.lpm.2016.11.014_bib0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2012.05.027","article-title":"Synthetic cannabinoids in \u201cspice-like\u201d herbal blends: first appearance of JWH-307\u00a0and recurrence of JWH-018\u00a0on the German market","volume":"222","author":"Ernst","year":"2012","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.lpm.2016.11.014_bib0055","series-title":"Thematic paper \u2013 Understanding the \u201cSpice\u201d phenomenon","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2009"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.014_bib0060","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jms.1811","article-title":"Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds","volume":"45","author":"Dresen","year":"2010","journal-title":"J Mass Spectrom"},{"issue":"2\u20133","key":"10.1016\/j.lpm.2016.11.014_bib0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2011.01.066","article-title":"CP47,497-C8\u00a0and JWH073, commonly found in \u201cSpice\u201d herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists","volume":"659","author":"Atwood","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.lpm.2016.11.014_bib0070","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.forsciint.2013.10.002","article-title":"Forensic investigation of K2, Spice, and \u201cbath salt\u201d commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds","volume":"233","author":"Seely","year":"2013","journal-title":"Forensic Sci Int"},{"issue":"7","key":"10.1016\/j.lpm.2016.11.014_bib0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.biopsych.2016.02.001","article-title":"Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis","volume":"79","author":"Fattore","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5409\/wjcp.v5.i1.16","article-title":"Synthetic cannabinoids 2015: an update for pediatricians in clinical practice","volume":"5","author":"Castellanos","year":"2016","journal-title":"World J Clin Pediatr"},{"key":"10.1016\/j.lpm.2016.11.014_bib0085","series-title":"New psychoactive substances in Europe. An update from the EU early warning system (March\u00a02015)","first-page":"7","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2015"},{"key":"10.1016\/j.lpm.2016.11.014_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnbeh.2011.00060","article-title":"Beyond THC: the new generation of cannabinoid designer drugs","volume":"5","author":"Fattore","year":"2011","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.lpm.2016.11.014_bib0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/SAR.S73586","article-title":"Emerging drugs of abuse: current perspectives on synthetic cannabinoids","volume":"6","author":"Debruyne","year":"2015","journal-title":"Subst Abus Rehabil"},{"key":"10.1016\/j.lpm.2016.11.014_bib0100","series-title":"Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances","first-page":"11","author":"Abdulrahim","year":"2015"},{"issue":"52","key":"10.1016\/j.lpm.2016.11.014_bib0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7748\/ns.28.52.35.e8850","article-title":"A critical analysis of national policy relating to legal highs","volume":"28","author":"Sarpong","year":"2014","journal-title":"Nurs Stand"},{"issue":"24","key":"10.1016\/j.lpm.2016.11.014_bib0110","first-page":"6171","article-title":"Schedules of controlled substances: temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule\u00a0I. Final order","volume":"81","author":"Drug Enforcement Administration DoJ","year":"2016","journal-title":"Fed Regist"},{"issue":"20","key":"10.1016\/j.lpm.2016.11.014_bib0115","first-page":"5042","article-title":"Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule\u00a0I. Final order","volume":"80","author":"Drug Enforcement Administration DoJ","year":"2015","journal-title":"Fed Regist"},{"issue":"24","key":"10.1016\/j.lpm.2016.11.014_bib0120","first-page":"6175","article-title":"Schedules of controlled substances: extension of temporary placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule\u00a0I of the controlled substances Act. Final order","volume":"81","author":"Drug Enforcement Administration DoJ","year":"2016","journal-title":"Fed Regist"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/add.13056","article-title":"The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015","volume":"111","author":"Mounteney","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.lpm.2016.11.014_bib0130","series-title":"Landmark law to tackle legal highs commences later this month","author":"Rt Hon Karen Bradley","year":"2016"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2515\/therapie\/2014235","article-title":"New synthetic drugs in addictovigilance","volume":"70","author":"Chavant","year":"2015","journal-title":"Therapie"},{"issue":"10026","key":"10.1016\/j.lpm.2016.11.014_bib0140","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(16)00619-X","article-title":"Public health and international drug policy","volume":"387","author":"Csete","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/08897077.2013.846288","article-title":"A survey of synthetic cannabinoid consumption by current cannabis users","volume":"35","author":"Gunderson","year":"2014","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/15563650.2014.885982","article-title":"Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances","volume":"52","author":"Archer","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.emc.2013.09.001","article-title":"Emerging drugs of abuse","volume":"32","author":"Nelson","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.lpm.2016.11.014_bib0165","series-title":"Drug misuse declared: findings from the 2010\/11\u00a0British crime survey","first-page":"11","author":"Smith","year":"2011"},{"key":"10.1016\/j.lpm.2016.11.014_bib0170","series-title":"Statistics OfN. Drug misuse declared: findings from the 2011\/12\u00a0Crime Survey for England and Wales","year":"2012"},{"key":"10.1016\/j.lpm.2016.11.014_bib0175","series-title":"Survey on alcohol and drugs in Spain (EDADES)","author":"Spanish Observatory on Drugs (SOOD)","year":"2013"},{"key":"10.1016\/j.lpm.2016.11.014_bib0180","author":"Inpes"},{"key":"10.1016\/j.lpm.2016.11.014_bib0185","first-page":"1","article-title":"Drug use among 17-year-olds: results of the ESCAPAD\u00a02014\u00a0survey","volume":"100","author":"Spilka","year":"2015","journal-title":"Tendances"},{"key":"10.1016\/j.lpm.2016.11.014_bib0190","series-title":"Monitoring the Future national survey results on drug use: 1975-2014: overview, key findings on adolescent drug use","author":"Johnston","year":"2015"},{"key":"10.1016\/j.lpm.2016.11.014_bib0195","series-title":"ESPAD Report 2015 - results from the European School Survey Project on Alcohol and Other Drugs","author":"ESPAD Group","year":"2015"},{"key":"10.1016\/j.lpm.2016.11.014_bib0200","series-title":"Hospital emergency presentations and acute drug toxicity in Europe: update from the Euro-DEN Plus research group and the EMCDDA","first-page":"14","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2016"},{"key":"10.1016\/j.lpm.2016.11.014_bib0205","series-title":"Drugs in Prison\u00a9 The Centre for Social Justice","year":"2015"},{"issue":"5","key":"10.1016\/j.lpm.2016.11.014_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/156800705774322111","article-title":"Cannabinoids","volume":"4","author":"Grotenhermen","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0215","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2\u00a0synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.lpm.2016.11.014_bib0225","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.neuropharm.2015.08.041","article-title":"Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid","volume":"99","author":"De Luca","year":"2015","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40429-014-0014-y","volume":"1","author":"Tai","year":"2014","journal-title":"Curr Addict Rep"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0235","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881114565142","article-title":"The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects","volume":"29","author":"Van Amsterdam","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study","volume":"197","author":"Morgan","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881114565142","article-title":"The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects","volume":"29","author":"Van Amsterdam","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.lpm.2016.11.014_bib0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.chroma.2016.02.047","article-title":"Assessment of ultra high performance supercritical fluid chromatography as a separation technique for the analysis of seized drugs: applicability to synthetic cannabinoids","volume":"1440","author":"Breitenbach","year":"2016","journal-title":"J Chromatogr A"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0255","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.lpm.2016.11.014_bib0260","first-page":"113","article-title":"Methods for the synthesis of cannabinergic ligands","volume":"123","author":"Thakur","year":"2006","journal-title":"Methods Mol Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The toxicology of bath salts: a review of synthetic cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J Med Toxicol"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.014_bib0270","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.lpm.2012.11.019","article-title":"Mephedrone: a new synthetic drug","volume":"42","author":"Petit","year":"2013","journal-title":"Presse Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0275","first-page":"53","article-title":"Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs","volume":"26","author":"Gurney","year":"2014","journal-title":"Forensic Sci Rev"},{"issue":"5","key":"10.1016\/j.lpm.2016.11.014_bib0280","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"Spice\u2019 and other herbal blends: harmless incense or cannabinoid designer drugs?","volume":"44","author":"Auwarter","year":"2009","journal-title":"J Mass Spectrom"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1465-3362.2012.00519.x","article-title":"Patterns of synthetic cannabinoid use in Australia","volume":"32","author":"Barratt MJ1","year":"2013","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.014_bib0290","first-page":"41","article-title":"Emerging drugs of abuse: clinical and legal considerations","volume":"97","author":"Aoun","year":"2014","journal-title":"Med Health R I"},{"key":"10.1016\/j.lpm.2016.11.014_bib0295","first-page":"77","article-title":"Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ Report. Rockville (MD): substance abuse and mental health services administration (US)","volume":"32","author":"Bush","year":"2013","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.lpm.2016.11.014_bib0300","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-015-0024-7","article-title":"Designer drugs\u00a02015: assessment and management","volume":"10","author":"Weaver","year":"2015","journal-title":"Addict Clin Pract"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0305","first-page":"177","article-title":"Acute intoxication caused by a synthetic cannabinoid in two adolescents","volume":"17","author":"Heath","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"9\u201310","key":"10.1016\/j.lpm.2016.11.014_bib0310","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/dta.1483","article-title":"Acute intoxication by synthetic cannabinoids \u2013 four case reports","volume":"5","author":"Hermanns-Clausen","year":"2013","journal-title":"Drug Test Anal"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5152\/tpa.2015.2609","article-title":"Cardiovascular side effects related with use of synthetic cannabinoids \u201cbonzai\u201d: two case reports","volume":"50","author":"Atik","year":"2015","journal-title":"Turk Pediatri Ars"},{"issue":"8","key":"10.1016\/j.lpm.2016.11.014_bib0320","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/15563650.2011.609822","article-title":"Severe toxicity following synthetic cannabinoid ingestion","volume":"49","author":"Lapoint","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"issue":"7","key":"10.1016\/j.lpm.2016.11.014_bib0325","doi-asserted-by":"crossref","first-page":"1320e5","DOI":"10.1016\/j.ajem.2011.05.013","article-title":"Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation","volume":"30","author":"Young","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0330","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40360-016-0045-1","article-title":"Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report","volume":"17","author":"McIlroy","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0335","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jemermed.2015.10.009","article-title":"Synthetic cannabinoids and their effects on the cardiovascular system","volume":"50","author":"Von Der Haar","year":"2016","journal-title":"J Emerg Med"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0340","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1345\/aph.1P580","article-title":"The \u201cnew\u201d marijuana","volume":"45","author":"Wells","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"168","key":"10.1016\/j.lpm.2016.11.014_bib0345","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/3-540-26573-2_20","article-title":"Cardiovascular pharmacology of cannabinoids","author":"Pacher","year":"2005","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.014_bib0350","doi-asserted-by":"crossref","first-page":"2055.e1","DOI":"10.1016\/j.ajem.2016.03.007","article-title":"Bradycardia and hypotension after synthetic cannabinoid use: a case series","volume":"34","author":"Kane","year":"2016","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0355","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13181-013-0288-9","article-title":"High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use","volume":"9","author":"Alhadi","year":"2013","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.lpm.2016.11.014_bib0360","doi-asserted-by":"crossref","first-page":"149A","DOI":"10.1378\/chest.1119854","article-title":"Diffuse alveolar hemorrhage: add \u201cgreenhouse effect\u201d to the growing list","volume":"140","author":"Loschner","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2016.11.014_bib0365","article-title":"Notes from the field: severe illness associated with synthetic cannabinoid use \u2013 Brunswick, Georgia, 2013","author":"Drenzek","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lpm.2016.11.014_bib0370","first-page":"2015","article-title":"Synthetic cannabinoids as a cause for black carbonaceous bronchoalveolar lavage","author":"Biswas","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"25","key":"10.1016\/j.lpm.2016.11.014_bib0375","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.2174\/13816128113199990620","article-title":"Acute and long-term effects of cannabis use: a review","volume":"20","author":"Karila","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0380","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jemermed.2012.11.034","article-title":"A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids","volume":"45","author":"Hopkins","year":"2013","journal-title":"J Emerg Med"},{"issue":"11","key":"10.1016\/j.lpm.2016.11.014_bib0385","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2215\/CJN.00360114","article-title":"Nephrotoxic effects of common and emerging drugs of abuse","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.lpm.2016.11.014_bib0395","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpba.2015.05.022","article-title":"Determination of XLR-11\u00a0and its metabolites in hair by liquid chromatography-tandem mass spectrometry","volume":"114","author":"Park","year":"2015","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.014_bib0400","first-page":"93","article-title":"Prevention. Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012","volume":"62","author":"Centers for Disease C.","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0405","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/15563650.2013.770870","article-title":"Synthetic cannabinoid use associated with acute kidney injury","volume":"51","author":"Thornton","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0410","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4103\/1319-2442.160222","article-title":"A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids","volume":"26","author":"Kamel","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.lpm.2016.11.014_bib0415","doi-asserted-by":"crossref","first-page":"235982","DOI":"10.1155\/2015\/235982","article-title":"Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids","volume":"2015","author":"Zhao","year":"2015","journal-title":"Case reports in nephrology"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0420","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3371\/CSRP.DUDE.031513","article-title":"Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report","volume":"8","author":"Durand","year":"2015","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0425","doi-asserted-by":"crossref","first-page":"121e1","DOI":"10.1016\/j.ajem.2015.05.052","article-title":"Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids","volume":"34","author":"Sweeney","year":"2016","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.lpm.2016.11.014_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15569527.2016.1169541","article-title":"Dermatological aspects of synthetic cannabinoid addiction","author":"Inci","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"issue":"6","key":"10.1016\/j.lpm.2016.11.014_bib0435","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4062\/biomolther.2015.057","article-title":"Neurotoxicity of synthetic cannabinoids JWH-081\u00a0and JWH-210","volume":"23","author":"Cha","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"issue":"8","key":"10.1016\/j.lpm.2016.11.014_bib0440","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/jat\/bku048","article-title":"Four post-mortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22","volume":"38","author":"Behonick","year":"2014","journal-title":"J Anal Toxicol"},{"issue":"13","key":"10.1016\/j.lpm.2016.11.014_bib0445","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/WNL.0000000000001973","article-title":"Hemorrhagic stroke following use of the synthetic marijuana \u201cspice\u201d","volume":"85","author":"Rose","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.lpm.2016.11.014_bib0450","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3109\/15563650.2014.958614","article-title":"A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid","volume":"52","author":"Takematsu","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"issue":"5","key":"10.1016\/j.lpm.2016.11.014_bib0455","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.030","article-title":"Synthetic cannabis and acute ischemic stroke","volume":"23","author":"Bernson-Leung","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"24","key":"10.1016\/j.lpm.2016.11.014_bib0460","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1212\/01.wnl.0000437297.05570.a2","article-title":"Ischemic stroke after use of the synthetic marijuana \u201cspice\u201d","volume":"81","author":"Freeman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2016.11.014_bib0465","doi-asserted-by":"crossref","first-page":"310930","DOI":"10.1155\/2015\/310930","article-title":"Synthetic cannabis-induced mania","volume":"2015","author":"Ustundag","year":"2015","journal-title":"Case reports in psychiatry"},{"issue":"Pt 1","key":"10.1016\/j.lpm.2016.11.014_bib0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2015.10.013","article-title":"The behavioral profile of spice and synthetic cannabinoids in humans","volume":"126","author":"M\u00fcller","year":"2016","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0475","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1521-0391.2012.00222.x","article-title":"Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient","volume":"21","author":"Peglow","year":"2012","journal-title":"Am J Addict"},{"key":"10.1016\/j.lpm.2016.11.014_bib0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.forsciint.2016.01.018","article-title":"Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC","volume":"265","author":"Klavz","year":"2016","journal-title":"Forensic Sci Int"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0485","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.3928\/01477447-20140401-62","article-title":"Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations","volume":"37","author":"Meijer","year":"2014","journal-title":"Orthopedics"},{"issue":"1","key":"10.1016\/j.lpm.2016.11.014_bib0490","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ajad.12318","article-title":"Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis","volume":"25","author":"Khan","year":"2016","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0495","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13181-016-0558-4","article-title":"Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose","volume":"12","author":"Zaurova","year":"2016","journal-title":"J Med Toxicol"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.014_bib0500","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3109\/15563650.2015.1100306","article-title":"An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA","volume":"53","author":"Tyndall","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0505","first-page":"150","article-title":"Acute psychosis after consumption of synthetic cannabinoids","volume":"84","author":"Morkl","year":"2016","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.1016\/j.lpm.2016.11.014_bib0510","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fnins.2016.00153","article-title":"Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants","volume":"10","author":"Miliano","year":"2016","journal-title":"Front Neurosci"},{"issue":"11","key":"10.1016\/j.lpm.2016.11.014_bib0515","doi-asserted-by":"crossref","first-page":"1712e3","DOI":"10.1016\/j.ajem.2015.03.025","article-title":"Withdrawal seizures seen in the setting of synthetic cannabinoid abuse","volume":"33","author":"Sampson","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0520","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dar.12225","article-title":"Synthetic cannabinoid withdrawal: a new demand on detoxification services","volume":"34","author":"Macfarlane","year":"2015","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0525","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.emc.2015.07.006","article-title":"New drugs of abuse and withdrawal syndromes","volume":"33","author":"Andrabi","year":"2015","journal-title":"Emerg Med Clin North Am"},{"issue":"27","key":"10.1016\/j.lpm.2016.11.014_bib0530","first-page":"464","article-title":"Withdrawal phenomena and dependence syndrome after the consumption of \u201cspice gold\u201d","volume":"106","author":"Zimmermann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.lpm.2016.11.014_bib0535","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0b013e31828e1881","article-title":"The synthetic cannabinoid withdrawal syndrome","volume":"7","author":"Nacca","year":"2013","journal-title":"J Addict Med"},{"key":"10.1016\/j.lpm.2016.11.014_bib0540","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.forsciint.2015.12.046","article-title":"Synthetic cannabinoid drug use as a cause or contributory cause of death","volume":"260","author":"Labay","year":"2016","journal-title":"Forensic Sci Int"},{"issue":"2","key":"10.1016\/j.lpm.2016.11.014_bib0545","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11419-015-0272-y","article-title":"Post-mortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver","volume":"33","author":"Hasegawa","year":"2015","journal-title":"Forensic Toxicol"},{"key":"10.1016\/j.lpm.2016.11.014_bib0550","first-page":"120607","article-title":"A unique case of cardiac arrest following K2\u00a0abuse","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"Case Rep Cardiol"},{"issue":"10","key":"10.1016\/j.lpm.2016.11.014_bib0555","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/j.hlc.2015.04.176","article-title":"Teenage cardiac arrest following abuse of synthetic cannabis","volume":"24","author":"Davis","year":"2015","journal-title":"Heart Lung Circ"},{"issue":"3","key":"10.1016\/j.lpm.2016.11.014_bib0560","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jat\/bkv142","article-title":"Death associated with the use of the synthetic cannabinoid ADB-FUBINACA","volume":"40","author":"Shanks","year":"2016","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.lpm.2016.11.014_bib0565","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.forsciint.2016.03.004","article-title":"Death after use of the synthetic cannabinoid 5F-AMB","volume":"262","author":"Shanks","year":"2016","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.lpm.2016.11.014_bib0570","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.forsciint.2015.04.021","article-title":"Case reports of synthetic canabinoid XLR-11\u00a0associated fatalities","volume":"252","author":"Shanks","year":"2015","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.lpm.2016.11.014_bib0575","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.forsciint.2016.02.024","article-title":"Fatal intoxication with synthetic cannabinoid MDMB-CHMICA","volume":"261","author":"Adamowicz","year":"2016","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.lpm.2016.11.014_bib0580","series-title":"European drug report\u00a02014: trends and developments","first-page":"36","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2014"},{"key":"10.1016\/j.lpm.2016.11.014_bib0585","series-title":"EMCDDA\u2013Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), Joint Reports","first-page":"11","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2016"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216303876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216303876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T05:47:40Z","timestamp":1568699260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216303876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0755498216303876"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.11.014","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabino\u00efdes de synth\u00e8se\u00a0: une nouvelle matrice des addictions","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}